Floatz logo

Therapeutic Asset Ratings

420 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Surufatinib
Gastric Cancer
RenJi HospitalP2CCC (52)
[18f]f-resca-rt4
Urinary Bladder Carcinoma
RenJi HospitalP2/3CCC (52)
[18f]f-resca-rt4
Cholangiocarcinoma
RenJi HospitalP2/3CCC (52)
[18f]f-resca-rt4
Head And Neck Cancer
RenJi HospitalP2/3CCC (52)
[18F]F-RESCA-T4
Urinary Bladder Carcinoma
RenJi HospitalP2/3CCC (52)
[18F]F-RESCA-T4
Cholangiocarcinoma
RenJi HospitalP2/3CCC (52)
[18F]F-RESCA-T4
Head And Neck Cancer
RenJi HospitalP2/3CCC (52)
[68ga]ga-nota-rt4
Urinary Bladder Carcinoma
RenJi HospitalP2/3CCC (52)
[68ga]ga-nota-rt4
Cholangiocarcinoma
RenJi HospitalP2/3CCC (52)
[68ga]ga-nota-rt4
Head And Neck Cancer
RenJi HospitalP2/3CCC (52)
[68ga]ga-nota-t4
Urinary Bladder Carcinoma
RenJi HospitalP2/3CCC (52)
[68ga]ga-nota-t4
Cholangiocarcinoma
RenJi HospitalP2/3CCC (52)
[68ga]ga-nota-t4
Head And Neck Cancer
RenJi HospitalP2/3CCC (52)
Benmelstobart
Nonpapillary Renal Cell Carcinoma
RenJi HospitalP2CCC (51)
Catequentinib
Nonpapillary Renal Cell Carcinoma
RenJi HospitalP2CCC (51)
Cytosin-Arabinosid
Biliary Tract Cancer
RenJi HospitalP2CCC (51)
Cytosin-Arabinosid
Pancreas Cancer
RenJi HospitalP2CCC (51)
Daunorubicin
Biliary Tract Cancer
RenJi HospitalP2CCC (51)
Daunorubicin
Pancreas Cancer
RenJi HospitalP2CCC (51)
Serplulimab
Biliary Tract Cancer
RenJi HospitalP2CCC (51)
Surufatinib
Biliary Tract Cancer
RenJi HospitalP2CCC (51)
Narlumosbart
Plasma Cell Myeloma
RenJi HospitalP3CCC (50)
[18f]f-resca-rt4
Cervical Cancer
RenJi HospitalP2/3CCC (50)
[18f]f-resca-rt4
Endometrial Carcinoma
RenJi HospitalP2/3CCC (50)
[18f]f-resca-rt4
Liver Cancer
RenJi HospitalP2/3CCC (50)
Showing 126 to 150 of 420 assets
PreviousPage 6 of 17Next